IBA Wins Contract for 12 PET Tracer Systems
The company will supply a radiopharmaceutical producer with a national production network in the United States.
Updated on Oct. 15, 2026 in Manufacturing
Live Poll
Should healthcare manufacturers prioritize building excess production capacity ahead of patient demand?
IBA has secured a contract to deliver 12 Cyclone KIUBE 300 systems for high-volume commercial PET tracer production. The deal includes facility design, installation, commissioning, and staff training services.
Why it matters
Radiopharmaceutical production capacity currently serves as a critical gating factor for the market. This order allows the producer to scale its infrastructure to meet projected patient demand.
The Cyclone KIUBE 300 system produces up to 35 Ci of 18F in a two-hour run with a fleet uptime exceeding 97 percent. Each unit carries a price range between 2.5 million and 5 million euros.
The players
IBA
IBA is a global medical technology company headquartered in Belgium that specializes in particle accelerator technology.
The details
The systems will utilize Nirta HCFT 18F helium cooling targets to facilitate the production of fluorine-18 and potential future radiometal applications. IBA will manage the entire lifecycle of the deployment, including architectural design and site commissioning.
Timeline
October 15, 2026: IBA announced the contract order.
Market Landscape
This deal underscores the rapid industrialization of PET tracer manufacturing as firms move toward large-scale, centralized networks. By securing this volume, the producer positions itself ahead of competitors currently reliant on fragmented or smaller-scale facilities.
While this news concerns industrial infrastructure, it signals an eventual increase in the availability of diagnostic radiopharmaceuticals for patients. Hospitals and clinics should expect more reliable supply chains for critical imaging agents as this production network comes online.
The takeaway
Large-scale investment in automation is transforming medical diagnostics from localized production into a national industrial model. Healthcare providers should monitor these infrastructure shifts as they directly influence the diagnostic capacity of local hospitals.
Further reading
For more on the latest sector developments, visit the United States Manufacturing page.
More information
Find more details on the company and their systems at the IBA corporate information website.
Live Poll
Should healthcare manufacturers prioritize building excess production capacity ahead of patient demand?
